Abstract
Parrocha and Nowick review ongoing efforts to develop peptide immunotherapies and vaccines against Alzheimer's disease. Peptide immunotherapies in which antibodies against the beta amyloid peptide are administered have begun to be approved as treatments for Alzheimer's disease. Although the efficacy of these first‐generation drugs has been modest, it is hoped that subsequent immunotherapies, including those with antibodies against the tau protein, will be more efficacious. Vaccines that train the immune system to safely produce antibodies against beta amyloid and tau have proven more challenging to develop but hold the promise of preventing Alzheimer's disease in the broader population. (doi: 10.1002/pep2.24289) image
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
